INTELLIA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
INTELLIA THERAPEUTICS, INC. (NTLA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 82.40% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-06
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-06-30 was 82.40%, a 3.78% increase year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-03-31 was 83.70%, a 11.01% increase year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-09-30 was 77.50%, a 2.24% increase year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-06-30 was 79.40%, a 4.06% increase year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 76.00%, a 0.39% decline from fiscal 2024.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 76.30%, a 3.05% decline from fiscal 2023.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 78.70%, a 3.28% increase from fiscal 2022.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 76.20%, a 4.53% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 82.40% 10-Q · filed 2026-08-06 | 83.60% 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | 83.70% 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | 76.00% 10-K · filed 2026-02-26 | |||
| 2025-09-30 | 77.50% 10-Q · filed 2025-11-06 | 76.00% 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | 79.40% 10-Q · filed 2026-08-06 | 75.80% 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | 75.40% 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | 76.30% 10-K · filed 2026-02-26 | |||
| 2024-09-30 | 75.80% 10-Q · filed 2025-11-06 | 76.30% 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | 76.30% 10-Q · filed 2025-08-07 | 76.40% 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | 76.40% 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 78.70% 10-K · filed 2026-02-26 | |||
| 2023-09-30 | 78.70% 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | 78.80% 10-Q · filed 2024-08-08 | 78.70% 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | 78.70% 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 76.20% 10-K · filed 2025-02-27 | |||
| 2022-09-30 | 76.20% 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 77.90% 10-Q · filed 2023-08-03 | 76.20% 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | 75.90% 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | 72.90% 10-K · filed 2024-02-22 | |||
| 2021-09-30 | 75.20% 10-Q · filed 2022-11-03 | 72.70% 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | 73.00% 10-Q · filed 2022-08-04 | 72.20% 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | 72.00% 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | 67.80% 10-K · filed 2023-02-23 | |||
| 2020-09-30 | 70.80% 10-Q · filed 2021-11-04 | 67.60% 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | 70.20% 10-Q · filed 2021-08-05 | 67.30% 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | 66.70% 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | 68.10% 10-K · filed 2022-02-24 | |||
| 2019-09-30 | 67.50% 10-Q · filed 2020-11-05 | 68.30% 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | 67.90% 10-Q · filed 2020-08-06 | 68.60% 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | 69.20% 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | 87.10% 10-K · filed 2021-02-26 | |||
| 2018-09-30 | 87.70% 10-Q · filed 2019-10-31 | 88.90% 10-Q · filed 2019-10-31 | ||
| 2018-06-30 | 87.70% 10-Q · filed 2019-08-01 | 89.00% 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | 89.40% 10-Q · filed 2019-05-02 | |||
| 2017-12-31 | 93.90% 10-K · filed 2020-02-27 | |||
| 2017-09-30 | 95.40% 10-Q · filed 2018-10-31 | 93.00% 10-Q · filed 2018-10-31 | ||
| 2017-06-30 | 94.00% 10-Q · filed 2018-08-01 | 92.70% 10-Q · filed 2018-08-01 | ||
| 2017-03-31 | 92.60% 10-Q · filed 2018-05-01 | |||
| 2016-12-31 | 88.00% 10-K · filed 2019-02-27 | |||
| 2016-09-30 | 88.00% 10-Q · filed 2017-10-31 | |||
| 2016-06-30 | 87.90% 10-Q · filed 2017-08-01 | |||
| 2016-03-31 | 87.70% 10-Q · filed 2017-05-02 | |||
| 2015-12-31 | 82.60% 10-K · filed 2018-03-14 | |||
| 2015-09-30 | 79.40% 10-Q · filed 2016-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |